A 48-year-old man patient is receiving parental nutrition (PN) at the following intravenous rate of infusion on daily basis:
At 21:00 start PN at a rate of 40 ml/hr x 1hr
At 22:00 increase PN to a rate of 80 ml/hr x 12hr
At 10:00 reduce PN to a rate of 40 ml/hr x 1hr
At 11:00 stop PN
Which of the following best describes the mode of PN administration in this patient?
A. Continues PN
B. Peripheral PN
C. Home PN
D. Cyclic PN
The correct answer is D. Cyclic PN (Cyclic Parenteral Nutrition).
Explanation:
Cyclic PN refers to the infusion of parenteral nutrition over a specific portion of the day (typically 8 to 16 hours, often overnight) rather than continuously over a 24-hour period.
In this patient's regimen, the infusion begins at 21:00, ramps up, runs for 12 hours, ramps down, and then completely stops at 11:00 (a total infusion time of 14 hours), leaving the patient PN-free for 10 hours during the day.
The 1-hour ramp-up period (40 mL/hr) at the start and the 1-hour ramp-down period (40 mL/hr) at the end are standard practices in cyclic PN to prevent sudden hyperglycemia and rebound hypoglycemia, respectively.
Why the other options are incorrect:
A. Continuous PN: Administered continuously at a constant rate over a full 24-hour cycle.
B. Peripheral PN: Refers to the route/site of access (peripheral vein vs. central line), not the mode/schedule of infusion.
C. Home PN: Refers to the location of administration (home vs. hospital), which cannot be determined solely by the infusion schedule.
Exam takeaway
Cyclic PN = PN infused for part of the day, followed by a planned period without infusion.
Key distinction: Continuous and cyclic PN describe the infusion schedule, peripheral PN describes the venous access route, and home PN describes the care setting.
Which of the following drugs can be safely recommended to a patient that has been suffering from chronic constipation?
A. Glycerol suppository
B. Ispaghula husk
C. Bisacodyl
D. Senna
The correct answer is B. Ispaghula husk.
Explanation:
Ispaghula husk (Psyllium) is a bulk-forming laxative and is recommended as the first-line agent for long-term/chronic constipation management. It works naturally by absorbing water in the gut, swelling to increase stool mass, and stimulating peristalsis. It has a high safety profile, does not cause dependency, and is safe for extended daily use, provided there are no contraindications such as intestinal obstruction or difficulty swallowing.
Why the other options are not ideal for long-term chronic use:
A. Glycerol suppository: This is a rectal stimulant/osmotic laxative intended for acute relief or acute fecal impaction rather than continuous daily management of chronic constipation.
C. Bisacodyl & D. Senna: These are stimulant laxatives. While effective for short-term relief or acute constipation, prolonged chronic use of stimulant laxatives is generally discouraged as a primary long-term strategy because they can cause abdominal cramping, electrolyte imbalances, and tolerance over time.
Exam takeaway
Chronic constipation → consider a bulk-forming laxative such as ispaghula husk first, provided the patient has adequate fluid intake and no obstruction or other contraindication.
Clinical note: If constipation persists despite appropriate fiber and fluid intake, reassess the cause, medications, and need for an osmotic laxative such as polyethylene glycol (macrogol).
Which of the following anti-arrhythmic drugs can is considered a rate control drug?
A. Sotalol
B. Flecainide
C. Amidarone
D. Propofenone
Correct answer: C. Amiodarone (likely the intended answer among the given options, but the question is somewhat ambiguous).
Explanation:
Rate control aims to control the ventricular heart rate, particularly in patients with atrial fibrillation (AF), without necessarily restoring normal sinus rhythm.
Amiodarone is a Class III antiarrhythmic drug that also has beta-blocking and calcium-channel-blocking effects. These actions can slow atrioventricular (AV) nodal conduction and reduce the ventricular rate, especially in selected patients with AF when other agents are unsuitable.
Why are the other options incorrect?
- A. Sotalol: A Class III antiarrhythmic with beta-blocking activity, used primarily for rhythm control; it can also slow heart rate.
- B. Flecainide: A Class Ic antiarrhythmic used primarily for rhythm control in selected patients with atrial arrhythmias.
- C. Amiodarone — Intended answer: Can slow AV nodal conduction and help control ventricular rate in selected circumstances, although it is primarily classified as a rhythm-control drug.
- D. Propafenone: A Class Ic antiarrhythmic used primarily for rhythm control; it also has some beta-blocking activity.
Important exam point:
For atrial fibrillation rate control, the usual first-line drugs are:
- Beta-blockers: e.g., metoprolol.
- Non-dihydropyridine calcium channel blockers: e.g., diltiazem or verapamil.
- Digoxin: useful in selected patients, particularly those with heart failure or limited activity.
Amiodarone is not generally a first-line rate-control drug because of its potential for significant long-term toxicities. If this is a single-best-answer MCQ, C is likely intended, but the question would be clearer if it specified a clinical scenario in which conventional rate-control agents are unsuitable.
Feature | Sotalol | Amiodarone |
|---|---|---|
Classification | Class III + Class II (non-selective beta-blocker) | Primarily Class III, with multiple channel-blocking effects |
Slows heart rate? | Yes, through beta-blockade | Yes, including effects on AV nodal conduction |
Primary role in AF | Rhythm control | Primarily rhythm control; can provide rate control in selected situations |
Standard first-line rate control? | No | No |
Important safety concern | QT prolongation and torsades de pointes | Thyroid, pulmonary, hepatic and other toxicities |
A 55-year-old man is being treated with IV acyclovir for herpes simplex virus (HSV) encephalitis. He wants to know if he can receive varicella vaccine today.
Which of the following should be the best response?
A. yes, because it is important to prevent future HSV infection
B. yes, because varicella vaccine is not related to HSV infection
C. no, because varicella vaccine may not work if given today
D. no, because he is currently acutely ill
The correct answer is C. no, because varicella vaccine may not work if given today.
Explanation:
Antiviral Interaction: The varicella vaccine is a live attenuated vaccine. Systemic antiviral medications with activity against herpesviruses—such as acyclovir, valacyclovir, and famciclovir—inhibit the replication of the live vaccine virus.
If administered while the patient is receiving IV acyclovir, the drug will neutralize the vaccine virus before an effective immune response can be mounted, rendering the vaccine ineffective.
Guideline Recommendation: Antiviral agents active against herpesviruses must be discontinued at least 24 hours prior to administering live varicella or zoster vaccines and avoided for 14 days after vaccination.
Why the other options are incorrect:
A & B: Incorrect because administering the vaccine while on acyclovir prevents the vaccine from working effectively. Additionally, while HSV and VZV are distinct viruses, acyclovir acts against both.
D: While moderate to severe acute illness is a general precaution for vaccination, the pharmacological contraindication/drug interaction (acyclovir directly inactivating the live vaccine) is the primary pharmacological reason why the vaccine cannot be given today.
Exam takeaway
Acyclovir + live varicella vaccine = potential reduced vaccine effectiveness.
Remember that the varicella vaccine is live attenuated, whereas the recombinant zoster vaccine (Shingrix) is non-live and is not affected by acyclovir in the same way.
Clinical note: In this case, the patient has HSV encephalitis, a serious acute illness, so vaccination should be deferred during the acute episode as well. The antiviral interaction is the likely intended examination concept, but both factors support postponing vaccination.
A 55-year-old man with a history of recurrent back pain is admitted to the hospital, he was prescribed paracetamol 1000 mg P.O Q6hr PRN for 1 month available tablet is 500mg.
What is the maximum quantity given for a refill?
A.8 tablets
B. 24 tablets
C. 42 tablets
D. 240 tablets
Correct Answer: D. 240 tablets
Explanation:
The prescription is for paracetamol 1,000 mg orally every 6 hours as needed (PRN) for 1 month. Each available tablet contains 500 mg.
Step 1: Calculate tablets per dose: 1000mg÷500mg/tablet=2tablets
Step 2: Calculate the maximum doses per day.
Every 6 hours means: 24hours÷6hours=4doses/day
Step 3: Calculate the maximum tablets per day.
2tablets/dose x 4doses/day= 8tablets/day
Step 4: Calculate the quantity for 30 days.
8tablets/day x 30days = 240tablets
Why are the other options incorrect?
- A. 8 tablets: The maximum daily quantity, not the monthly quantity.
- B. 24 tablets: Does not account for the prescribed maximum daily use over 30 days.
- C. 42 tablets: Does not correspond to the maximum quantity for the prescribed duration.
Exam takeaway
For PRN prescriptions, calculate the maximum possible use using the prescribed dose, maximum frequency, tablet strength, and duration.
Clinical safety note: This prescription permits up to 4,000 mg of paracetamol daily. Although this is the traditional maximum for some healthy adults, many guidelines recommend a lower maximum, especially for patients with liver disease, regular alcohol use, malnutrition, or other risk factors. The prescribed regimen should be reviewed for safety.
Which of the following is the recommended anti-coagulation strategy for atrial fibrillation patient with a CHA₂DS₂-VASc score of 5?
A. aspirin
B. dabigatran
C. clopidogrel
D. no anticoagulation
The correct answer is B. dabigatran.
Explanation:
The CHA₂DS₂-VASc score estimates the risk of stroke in patients with atrial fibrillation (AF) and helps guide decisions about oral anticoagulation.
CHA₂DS₂-VASc Score Interpretation: A CHA₂DS₂-VASc score of 5 places a patient with non-valvular atrial fibrillation (AF) at high risk for ischemic stroke and thromboembolism.
According to ACC/AHA/HRS and ESC guidelines, oral anticoagulation is strongly recommended for men with a score ≥2 and women with a score ≥3.
Direct Oral Anticoagulants (DOACs) as First-Line: Dabigatran is a Direct Thrombin Inhibitor (a DOAC). Clinical practice guidelines recommend DOACs (e.g., dabigatran, apixaban, rivaroxaban) over warfarin and antiplatelet therapy for stroke prevention in non-valvular AF due to lower risks of major bleeding (especially intracranial hemorrhage) and lack of daily INR monitoring.
Why the other options are incorrect:
A. Aspirin & C. Clopidogrel: Antiplatelet agents are not recommended for stroke prevention in atrial fibrillation regardless of stroke risk. Studies show they offer significantly lower efficacy for stroke prevention compared to oral anticoagulants without a meaningful reduction in bleeding risk.
D. No anticoagulation: With a score of 5, withholding therapy leaves the patient at a dangerously high risk of a severe thromboembolic stroke.
Exam takeaway
Atrial fibrillation + CHA₂DS₂-VASc score of 5 → oral anticoagulation is generally indicated.
Other suitable options include apixaban, rivaroxaban, and edoxaban. Warfarin is preferred for patients with mechanical heart valves or moderate-to-severe rheumatic mitral stenosis.
Clinical note: The choice and dose of anticoagulant depend on renal function, bleeding risk, drug interactions, and the presence of contraindications.
Which of the following is most appropriate to give hepatitis B vaccine for unvaccinated patient?
A. 1 dose vaccine intramuscularly
B. no vaccination is recommended
C. 1 dose vaccine intramuscularly every year
D. 3 doses vaccine series administered intramuscularly at 0, 1, and 6 months
The correct answer is D. 3 doses vaccine series administered intramuscularly at 0, 1, and 6 months.
Explanation:
The hepatitis B vaccine protects against infection with the hepatitis B virus (HBV), which can cause chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
Standard Schedule: The standard primary vaccination schedule for an unvaccinated individual (adults, adolescents, and children) using conventional single-antigen Hepatitis B vaccines (such as Engerix-B or Recombivax HB) consists of 3 intramuscular doses:
First dose: Given at time 0 (baseline).
Second dose: Given 1 month after the first dose.
Third dose: Given 6 months after the first dose.
Completing all 3 doses ensures long-term seroprotective immunity (anti-HBs ≥10 mIU/mL).
The vaccine is administered intramuscularly, usually in the deltoid muscle in adults.
Why the other options are incorrect:
A. 1 dose vaccine intramuscularly: A single dose is insufficient to produce adequate or long-lasting protective antibodies against Hepatitis B.
B. No vaccination is recommended: Unvaccinated individuals are susceptible to Hepatitis B virus infection and should receive the complete vaccine series.
C. 1 dose vaccine intramuscularly every year: Unlike the annual influenza vaccine, the Hepatitis B vaccine is not given as a recurring annual shot. Once the primary series is completed, booster doses are generally not needed for immunocompetent individuals.
Exam takeaway
Hepatitis B vaccine: 0, 1, and 6 months (three-dose schedule).
Clinical note: Not all hepatitis B vaccines require three doses. Some adult formulations use a two-dose schedule, and certain combination vaccines use different schedules. Always check the specific vaccine product and local immunization guidelines.
To read more such exam questions with explanation visit the blog or click on Prometric Exams
Related Keywords: Clinical Pharmacy MCQs, Hospital Pharmacist Exam Questions, Pharmacotherapy MCQs, Pharmacy Licensing Exam Preparation, Clinical Pharmacy Questions and Answers, NAPLEX Practice Questions, Hospital Pharmacy MCQs, Drug Therapy Questions, Pharmacy Exam Preparation, DHA MOH Prometric Exam Preparation.
0 Comments